Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -92.72% |
| Total Other Revenue | -- | -- | -- | -24,025.00% | -102.15% |
| Total Revenue | -- | -- | -- | -24,025.00% | -102.06% |
| Cost of Revenue | -- | -- | -- | 12,718.49% | -59.94% |
| Gross Profit | -- | -- | -- | -13,019.03% | 40.67% |
| SG&A Expenses | -- | -- | -- | -7.24% | 32.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -23.22% | -9.60% |
| Operating Income | -- | -- | -- | 22.99% | -1.49% |
| Income Before Tax | -- | -- | -- | 28.19% | 6.13% |
| Income Tax Expenses | -- | -- | -- | 56.03% | 36.55% |
| Earnings from Continuing Operations | -- | -- | -- | 28.01% | 5.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 28.01% | 5.91% |
| EBIT | -- | -- | -- | 22.99% | -1.49% |
| EBITDA | -- | -- | -- | 23.88% | -1.83% |
| EPS Basic | -- | -- | -- | -55,719.18% | -62,125.19% |
| Normalized Basic EPS | -- | -- | -- | -56,040.66% | -62,981.48% |
| EPS Diluted | -- | -- | -- | -55,719.18% | -57,304.93% |
| Normalized Diluted EPS | -- | -- | -- | -56,040.66% | -62,981.48% |
| Average Basic Shares Outstanding | -- | -- | -- | -42.37% | -48.51% |
| Average Diluted Shares Outstanding | -- | -- | -- | -42.37% | -48.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |